Navigation Links
Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
Date:5/14/2009

for the treatment of pain and fever in the United States and is available in more than 600 combination and single-ingredient prescription and over-the-counter products. Cadence acquired the exclusive rights to Acetavance in the United States and Canada in 2006 from Bristol-Myers Squibb Company, which markets the product as Perfalgan(R) in Europe and other parts of the world. Intravenous acetaminophen is approved in approximately 80 countries, including major markets in Europe, where the product is the market leader among all injectable analgesics. Approximately 90 million vials of intravenous acetaminophen were sold in Europe in 2008.

There is an unmet medical need for new agents to treat pain or fever in hospitalized patients who cannot take medications by mouth. Only two classes of intravenous analgesics, opioids and non-steroidal anti-inflammatory drugs, or NSAIDs, are currently available in the United States for the treatment of acute pain. Opioids may be associated with a variety of unwanted side effects, including respiratory depression, excessive sedation, nausea, vomiting, constipation, cognitive impairment, and others. The only non-opioid intravenous analgesic currently available in the United States is the NSAID, ketorolac. Post-operative use of intravenous ketorolac is limited due to its potential to cause increased bleeding. Renal toxicity and the potential for increased cardiovascular events further limit the post-operative use of NSAIDs. Dipyrone (metamizole) was the last injectable drug for the reduction of fever in the United States, but since it was taken off the market in 1976, there has been no approved parenteral antipyretic drug available.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Ac
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
2. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
4. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
5. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
6. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
7. Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
8. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
9. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting
10. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Lazarus Effect, a medical device ... to facilitate removal of blood clots, announced the closing ... will support EU commercialization of several approved Lazarus Effect ... ReCover™ and Lazarus Cover™ in the United ... confidence in the value of our novel, platform technology ...
(Date:7/31/2014)... and VIENNA , July 31, ... a press conference in New York ... a vaccine against Parkinson,s disease. PD01A is the first therapy ... enter clinical testing. The Michael J. Fox Foundation ... 1.5 million grant, and presented at the press conference on ...
(Date:7/31/2014)... NORTHBROOK, Ill. , July 31, 2014 /PRNewswire/ ... as the head of corporate and employee communications ... to Jeff Winton , senior vice president, ... be responsible for developing and leading corporate brand ... business goals across North and South ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4Astellas Hires Industry Veteran Moyra Knight as Head of Corporate and Employee Communications 2
... ... research and biotechnology companies are testing 97 medicines and vaccines to ... report released today by the Pharmaceutical Research and Manufacturers of America ... - a global awareness campaign that originated at the 1988 World ...
... , XI,AN, China, Nov. ... a leading developer and producer,of plant extracts and pharmaceutical raw ... China, today reported that in its,third quarter, the company realized ... Revenues for the quarter ended Sept. 30, 2009 were $4,465,770, ...
Cached Medicine Technology:New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 2New Report Shows 97 Medicines and Vaccines Currently in Development for HIV/AIDS 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 4
(Date:7/31/2014)... 2014 The team at Advanced ... NJ, is proud to announce that they are ... PMR proudly offers many services, including Physical Therapy, ... medical supplies. Some of their physical therapy services ... geriatric therapy among a vast list of others. ...
(Date:7/31/2014)... In a front-page story, the Wall ... & Johnson, is withdrawing its laparoscopic power morcellator due ... This important story has also been reported by ... AP (7/30), the Pittsburgh Business Times (7/30) and TIME ... uterine procedures to, “slice up common uterine masses called ...
(Date:7/31/2014)... , Rest assured, there is a happy ending, ... shows that many college students are stressed out and ... there are simple ways for students to relieve stress ... of UC,s Health Promotion and Education Program. The trouble ... a whole array of different stress-management techniques college students ...
(Date:7/31/2014)... The Never Give Up 26 Foundation looks forward to seeing ... Simply bring your ticket and Mention Never Give Up 26 ... and family. , Packy had unique internal drives, ... optimism continues to impact the lives of many. Overcoming ... a happy life was truly a testament to his character. ...
(Date:7/31/2014)... The “Nucleic Acid Isolation and Purification ... bead based), Consumables & Instruments, by Application (Plasmid ... users - Global Forecasts to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... with the estimates and forecasts of the revenue ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs' Approved, Advanced Physical Medicine and Rehabilitation Now Offering Chiropractic & Podiatric Services 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 3Health News:Simple tips to fend off freak-outs 2Health News:Simple tips to fend off freak-outs 3Health News:Don't Forget To Mention Never Give Up 26 Foundation 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 4
... that has been commissioned by the Australian government states that ... cost effective option to control// the growing epidemic of childhood ... found the various programs based in schools were cost-effective, but ... that many ministers for state who are in favour of ...
... Canada can differ according to provinces, says a new study ... ,People on dialysis in Alberta were four times more ... the study conducted over a five-year period found. Saskatchewan, Atlantic ... for kidneys than Ontario. ,"We can say that ...
... The National Institute of Virology in Pune declared Tuesday there ... 250 km from here in south Gujarat.// ,Additional ... samples from Surat city, and not even a single sample ... NIV, have not yet clarified why two persons had died ...
... August 26 issue of "The Lancet" has revealed that ... past decade// in many countries of the world, especially ... University of Auckland, New Zealand, and colleagues repeated the ... between 2002-2003 to assess the global prevalence of asthma, ...
... a Christchurch General Practitioner for allegedly manipulating a sexual ... account, the GP even bought her lingerie and advised ... ,The doctor has been slapped with a charge ... with the woman in question. Allegedly, the former ...
... Board has indicated that the Klein Government is all set ... early stage breast cancer.// The spokeswoman of the board, Lee ... trials in the United Kingdom before advising the $40,000-per-patient drug ... is available to those patients who are in dire need ...
Cached Medicine News:Health News:Health Experts In Australia Toy With The Idea Of Surgery for Controlling Obesity In Teenagers 2Health News:Rise In Childhood Allergies 2
7 mm curved blade. Round handle....
7 mm strong curved blade. Round handle....
3 mm diameter roller blade, 15 mm from angle to tip. Round handle....
No. 4. 0.75 mm wide x 5 mm long, lightly curved tip, offset to the left. Hexagonal handle....
Medicine Products: